Biosurgery Product Market
The market for Biosurgery Product was estimated at $11.6 billion in 2024; it is anticipated to increase to $17.1 billion by 2030, with projections indicating growth to around $23.7 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Biosurgery Product Market Outlook
Revenue, 2024
$11.6B
Forecast, 2034
$22.2B
CAGR, 2025 - 2034
6.7%
The Biosurgery Product industry revenue is expected to be around $12.4 billion in 2025 and expected to showcase growth with 6.7% CAGR between 2025 and 2034. The biosurgery sector is becoming increasingly crucial in providing improved surgical outcomes as it offers safer and more efficient surgical care options, largely due to a growing elderly population, the rise in procedure volumes and a preference for minimally invasive surgeries. High risk, complex procedures such as orthopaedic and cardiovascular surgery make up 57.7% of the market for hemostatic agents. These procedures rely heavily on products like haemostatic agents, surgical sealants and adhesion barriers to prevent and control bleeding. This can reduce complications and the length of time patients are in hospital.
They usually comprise biocompatible hemostatic agents, mechanical matrices, adhesion barriers, and surgical sealants and adhesives designed to promote tissue regeneration, optimize wound healing and to seal tissues at the point of surgery. These products offer the benefits of a rapid onset of action, strong bonding in wet environments, consistent resorption rates and compatibility with laparoscopic and robotic surgical procedures. This makes them useful in a variety of surgical fields including orthopaedic, cardiothoracic, general, neuro and gynaecological surgery. Growing demand is driven by several factors, these include an increase in the use of innovative biomaterials and biologic products, surgeons are now increasingly using biosurgery solutions in regenerative medicine and for advanced wound care. Additionally, pre assembled kits are also being developed. These are for use in the operating theatre and are in line with guidelines which help in faster recovery.
Market Key Insights
A forecast suggests biosurgery products will be worth twenty-two billion U.S. dollars in the year 2034. By 2024, the products will be worth eleven point six billion U.S. dollars. With a compound annual growth rate of 6.7%, the market has grown, thanks in part to growing demand in orthopaedic, cardiovascular and gynaecological surgical markets.
The main companies in this market include Johnson & Johnson Services Inc, BD and Baxter International, and they dominate the competitive landscape.
The US and China are the leading markets for biosurgery products, and are expected to experience a compound annual growth rate of 4.4 to 6.4 percent between 2024 and 2030.
The countries of India, South Korea and Brazil will grow at the fastest rate in the emerging markets sector, with growth rates increasing by between 7.7% and 9.2% per year.
The integration of clinical and data driven techniques is set to have a significant impact on the US and Chinese market's value chain. This is expected to boost the biosurgery products industry by $465 million by 2030.
Between 2024 and 2034, Biosurgery Product sales are predicted to reach $10.6 billion, driven primarily by the increasing sales of products used in cardiovascular surgery and neurosurgery applications.
With
rising adoption of minimally invasive and robotic surgeries accelerating demand for differentiated biosurgery product portfolios, and
Accelerating shift toward value-based healthcare models increasing clinical and economic appeal of biosurgery product solutions, Biosurgery Product market to expand 91% between 2024 and 2034.
Opportunities in the Biosurgery Product
An increase in the elderly population across Europe has a positive effect on spinal fusion and dental implants. This is increasing the demand for the materials used in these operations. Presently a market worth $3.15 billion globally by 2024, the bone graft substitutes sector is predicted to reach $4.38 billion in value by 2030 with a growth rate of 5.8% per annum. Companies that develop bone grafts which are three dimensional printed and osteoinductive, and also work with European dental and spine implant networks, may replace autografts and allografts. They could capture higher levels of reimbursement in countries such as France, Italy, Germany and the Nordic nations.
Growth Opportunities in North America and Asia Pacific
The biosurgery market in North America will be dominated by orthopedics due to the high number of hip and knee replacements, spinal surgeries and trauma operations, alongside sound clinical and insurance reimbursement policies and protocols aimed at the reduction of blood transfusions. The most promising business opportunities arise in high end biosurgery product lines that offer scientifically proven solutions which combine several products such as surgical sealants, advanced wound care products and haemostatic agents. These product lines have been designed specifically for orthopaedic applications including operations that are minimally invasive in outpatient facilities. Strong competition exists in the medical technology sector with numerous diversified and regional specialist companies offering a range of services and leveraging their contracting power. With bundled services becoming increasingly important, providers must differentiate their clinical offerings, demonstrate strong real world outcomes and also be integrated with digital care pathways if they wish to gain market share and negotiate higher prices.
Cardiovascular surgery in Asia Pacific is likely to be the biosurgery products market where there will be the most growth. This expansion will be driven by a significant increase in the number of operations for the heart and blood vessels, rising numbers of people suffering from cardiovascular disease and the considerable funding invested in hospitals in the regions major economies. Key opportunities exist with technologically advanced, cost effective biosurgical products which focus on intraoperative bleeding control, efficient adhesion prevention and flexible formats for operating theatres which perform a high volume of surgery. This is backed up by clinical training and local manufacturing or packaging. Domestic and regional industry leaders have grown in prominence, and their primary business strategy is to provide biosurgery products which focus on value for the end user. The position taken by these products in the market is determined by several key factors. Their pricing is competitive, and the companies are able to navigate the complex regulatory requirements affecting the industry with relative ease. Furthermore, biosurgery products are designed to be used by hospitals which are at different stages of development, while also adhering to government initiatives which are aimed at improving the standard of surgical procedures in the country.
Market Dynamics and Supply Chain
01
Driver: Rising adoption of minimally invasive and robotic surgeries accelerating demand for differentiated biosurgery product portfolios
Minimally invasive surgery is also now expanding and as a result is also changing our expectations regarding the clinical performance of each surgical device. Laparoscopic and endoscopic surgeons need high performance surgical adhesives and hemostats which offer quick control in confined areas with minimal swelling and strong adhesion for quicker recovery and shorter hospital stays. The increasing prevalence of robotic surgery has also given rise to a significant demand for specially designed biomaterials with the ability to ensure optimal performance of surgical instruments. These biomaterials have also to allow for precise control and clear visual observation during the procedure. Investment is also being made by medical equipment suppliers in pre loaded applicator systems designed for articulating robotic arms, in sprayable adhesion barriers and in flowable haemostats. These innovations at the product level are also changing the key factors which hospitals consider when making a purchase, shifting these considerations from generic biologics to biosurgical products. These are also ones which are also tailored to a procedure and improve operating theatre efficiency, the consistency of the procedure and patient results, and so influence hospital formularies.
With a growing interest in value based healthcare, medical suppliers are also expected to compare all biosurgery products in terms of their general expense over an entire treatment period and also long term effects on patients. High cost orthopaedic and spinal surgeries are also major areas of focus for integrated healthcare systems and hospitals in terms of cutting down postoperative issues, intraoperative bleeding, the need for reoperation and hospital stays. With the development of evidence based regenerative medicine, companies are also introducing technologies which are also backed by data. Real world patient data is also being collected and stored in registries. These registries track cost savings that come from better wound healing and reduced hospital readmissions. Bidding frameworks that reward value, quality and efficiency mean that the products with clinically proven technology, standardised delivery protocols and predictable performance are also being given preferential treatment by buyers in procurement contracts and strategic sourcing initiatives.
02
Restraint: Complex regulatory and reimbursement pathways significantly delay commercialization timelines for innovative biosurgery product portfolios
High risk medical devices and combination products which include biosurgery products are now classified by US regulatory agencies as such. These items require extensive follow up studies after they are brought to market for sale. This increases costs of developing haemostyptics and surgical adhesives, hinders their launch and decreases patent duration, resulting in lower total earnings. Procurement teams in hospitals are discouraged from adopting biosurgical products due to the uncertainty of reimbursement. This reduces the demand for biosurgical products and thus they have a smaller share of the market compared to conventional ones.
03
Opportunity: Untapped use of rapid hemostatic agents in emergency and trauma centers across tier 2 Indian cities and Rising demand for surgical sealants in minimally invasive cardiovascular and thoracic procedures across United States hospitals
Currently Indias non metropolitan towns are witnessing the development of their emergency medical facilities, yet the provision of advanced topical haemostatic agents is not only widespread, with many healthcare units employing conventional dressings and sutures. The biosurgery sector in which haemostats function is the largest area currently and is estimated to expand from US $3.69 billion in 2024 to US $5.36 billion in 2030 at a compound annual growth rate of 6.5%.The rapid adoption of fast acting gels, powders and dressings in emergency wards and ambulances across the country could be triggered by a variety of means. These include low cost formulations, the training of medical staff in emergency wards and in ambulances and localised manufacturing.
Cardio and thoracic surgeons in the US are increasingly opting for the minimally invasive and robotic techniques. This shift has led to a substantial demand for products which reduce the need for a second surgery by preventing leakage. The biosurgery sectors most rapidly increasing category is surgical sealants and adhesives. The projected increase in the global market is from $2.72 billion in 2024 to $4.32 billion in 2030, at a compound annual growth rate of 8.2%. Organisations making available easy to use, sprayable sealants which can be used in conjunction with robotics, who form partnerships with the leading US heart treatment centres, can seize annually the significant procedure volumes that go untried.
04
Challenge: High procedure costs and pricing pressures restrict hospital adoption of premium biosurgery product and biosurgical solutions
Complex biosurgery products used in orthopaedic surgery, heart operations and wound healing often cost over tightly managed budgets for these medical treatments. In a pay for performance environment hospitals are finding surgeons inclined towards lower cost options, especially in surgeries that involve a minimal invasion and are carried out a lot. This has a limiting effect on the number of medicines which can be listed on the formulary, and further leads to the restriction of the use of treatments where the results are better than those of others, along with heightened price competition. This results in a slowing of the growth of medicines which regenerate tissues.
Supply Chain Landscape
1
Regenerative Biomaterials Sourcing
BDIntegra LifeSciencesBaxter International
2
Biosurgery Product Manufacturing
Johnson & Johnson Services Inc.MedtronicBaxter International
3
Global Supply Distribution
Johnson & Johnson Services Inc.BDMedtronic
4
Surgical Care End-Users
Hospitals & Surgical CentersSpecialty ClinicsAcademic & Research Institutes
1
Regenerative Biomaterials Sourcing
BDIntegra LifeSciencesBaxter International
2
Biosurgery Product Manufacturing
Johnson & Johnson Services Inc.MedtronicBaxter International
3
Global Supply Distribution
Johnson & Johnson Services Inc.BDMedtronic
4
Surgical Care End-Users
Hospitals & Surgical CentersSpecialty ClinicsAcademic & Research Institutes
Use Cases of Biosurgery Product in Orthopedic Surgery & Gynecological Surgery
Orthopedic Surgery : In terms of size of application, biosurgery is likely to be used in orthopaedic surgery, generating US $4.2 billion in revenue by the year 2025 and projected to rise by 5.7% each year through 2030 due to an increase in the number of spinal and reconstructive surgical operations for older people. Products from the biosurgery category used in orthopaedic trauma comprise around 28.5% of the global demand for biosurgery products in 2025. Orthopaedic trauma biosurgery products are used for controlling bleeding in surgeries involving joint replacement and complex trauma cases, also stabilising fractures, and supporting the regrowth of tissue in spinal fusion. In addition to this they are also used to reinforce soft tissue in both open surgery and minimally invasive surgery. The companies Johnson &Johnson Services and Medtronic are leading in the development of orthopaedic biosurgery products. They supply a broad range of implants and grafts which they combine with surgical tools of the highest technology. Integra LifeSciences Corporation specializes in bone and soft tissue matrix products. These are used for reconstruction and trauma procedures of the limbs. These leaders are supported by Baxter International and Becton Dickinson who offer a range of haemostatic agents and methods of wound closure which find widespread application in orthopaedic theatres due to their ease of use and compatibility with current theatre workflows.
Cardiovascular Surgery : The cardiovascular surgery industry is a sector that will be witnessing high growth in the field of biosurgery products. The industry is expected to reach $2.49 billion by the year 2025. The growth in this industry is expected to be at the rate of 7.6% CAGR by 2030. This growth is due to an increase in the number of coronary bypass surgeries, aortic reconstruction and valve repair. In biosurgery these agents with the largest share of the market at 2025 are the haemostats. The haemostats which give rapid control of bleeding, are used at anastomotic sites, bio surgical sealants and adhesives which make up approximately 25.1% of the total demand are used to strengthen the sutures of blood vessels, to stop leaks at anastomotic sites and to seal grafts and patches. Johnson & Johnson Services Inc. and Baxter have a strong market presence in cardiovascular biosurgery products. This is due to their comprehensive product lines in haemostatic and sealant agents. These products are backed by significant clinical data as well as strong relationships with cardiac surgeons and perfusion specialists. The company Medtronic combines its strong position in aortic and structural heart therapies with the ability to incorporate biosurgery systems directly into their therapy systems. Becton Dickinson on the other hand offers various hemostasis tools for both medical professionals and patients.
Gynecological Surgery : A $0.95 billion gynecological surgery market will exist in 2025. This sector is likely to expand at a compound annual growth rate of 7.3% by 2030. Surgeons are doing more endometriosis procedures. This results in an increasing demand for medical supplies and instruments. Pelvic surgery often involves the utilization of surgical sealants and haemostatic agents, the latter being used to control diffuse haemorrhaging, to reduce the formation of scar tissue following surgery and protect the reproductive organs. The company Johnson & Johnson Services Inc. maintains a significant presence in gynaecological operating theatres with a variety of haemostats, tissue sealants and sutures designed to handle delicate tissues. Baxter is well known for the reliability of its biosurgery products in controlling venous and oozing bleeding which occurs during complex pelvic surgery. The company Integra LifeSciences has further developed its skills in tissue repair and nerves, in region's such as gynaecological cancer and reconstructive surgery. In womens healthcare, Becton Dickinson supports this region with its range of products for biosurgery, including tools for haemostasis, tissue management and endoscopic procedures.
Recent Developments
Recent biosurgery product developments indicate a significant rise in the use of bioresorbable sealants and advanced haemostatic agents in minimal access surgery. The number of procedures for soft tissue repair and for preventing tissue adhesions is increasing and this is driving market players to expand their product ranges in the field of regenerative medicine. Key amongst these are the fusion of biologicals and biomaterials with the next generation of wound dressings used in surgical procedures. This has the effect of reducing hospital stays and saving time in theatre.
July 2023 : Baxter completed the sale of its pharmaceutical production service to other companies. The companys financial situation has been improved allowing it to pursue its core goals more easily. It will also allow the company to use its money for its core objectives of making medical equipment for hospitals and operating theatres. This will enable further research into and the introduction of new biosurgical products.
May 2023 : Concerns about the quality control system at one of Integra LifeSciences Boston plant have prompted a worldwide halt in the production of a variety of biosurgery products, including regenerative matrices utilised in neurosurgery and reconstructive surgery, triggering a global shortage of these implants. Consequently, healthcare suppliers must change their suppliers and revise clinical guidelines which depend on advanced haemostatic agents and biosurgery products.
Impact of Industry Transitions on the Biosurgery Product Market
As a core segment of the Medical Device industry,
the Biosurgery Product market develops in line with broader industry shifts.
Over recent years, transitions such as Data Driven Clinical Integration and Regenerative, Minimally Invasive Focus have redefined priorities
across the Medical Device sector,
influencing how the Biosurgery Product market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Data Driven Clinical Integration
The biosurgery products market is shifting from a focus on commodity driven disposables to integrated solutions that prioritize clinical outcomes and data analytics. This transition is reshaping purchasing dynamics in orthopaedic and cardiovascular surgeries, where contracts increasingly favor biosurgical products backed by robust outcome data and compatibility with value based care models. As hospitals emphasize quality metrics and efficiency, the integration of clinical and data driven techniques is poised to enhance the value chain significantly, with projections indicating a $465 million boost to the biosurgery products industry by 2030. This strategic shift is not only influencing surgeon formularies but also redefining market preferences, positioning biosurgical solutions as critical components in improving surgical performance and patient outcomes.
02
Regenerative, Minimally Invasive Focus
The shift towards regenerative medicine, biosurgery products aimed at minimally invasive surgery and advanced wound healing are being developed. Companies are now replacing older materials used in surgery with new biomaterials, matrixes made from collagen and fibrin sealants. These technologies promote healing and reduce scarring. The development of new medical techniques and technologies has allowed for a greater number of operations to be carried out on an outpatient basis, including surgery for sports injuries, spinal problems and cosmetic defects. The more tissue repair products are tailored to individuals and contain living cells the more they will require new product sterilisation procedures and regulatory requirements.